Introduction
============

Several studies have consistently shown that drug prescribed for the treatment of COPD differs markedly from that recommended in current recommendation documents.[@b1-copd-13-2279],[@b2-copd-13-2279] In brief, the different available studies indicate that there is an overprescription of inhaled corticosteroids (ICSs), an underutilization of long-acting bronchodilators (LABDs), a use of oral treatments not always according to their formal indications, and a drug use in disagreement with different patient types.[@b3-copd-13-2279]--[@b8-copd-13-2279]

Despite the valuable information these studies provide, they are frequently based on automated databases that do not allow to understand the determinants of pharmacological prescription in daily clinical practice. Although some previous studies have assessed this aspect,[@b6-copd-13-2279],[@b7-copd-13-2279],[@b9-copd-13-2279],[@b10-copd-13-2279] most of these studies are conducted in primary care and evaluate only partial aspects of drug prescription. Accordingly, there is a need for a prospective, comprehensive evaluation on what are the key elements on which physicians base their therapeutic decisions in secondary care.

In this context, clinical audits have emerged as a new tool with potentials for describing the clinical behavior in a determined clinical context, time, and geographical area, with the potential of analyzing the determinants that explain this clinical behavior, and designing a feedback strategy with the final aim to improving health care.[@b11-copd-13-2279] COPD is a common, severe, and disabling condition but a preventable and treatable disease, and it has recently been assessed in clinical audits with the aim to highlight areas of improvement in daily clinical practice. Several recent initiatives have given valuable data on how COPD is delivered to patients in different clinical scenarios.[@b12-copd-13-2279]--[@b14-copd-13-2279]

Regarding pharmacological prescription in secondary care outpatients, a recent pilot clinical audit evaluated clinical performance of pulmonologists in COPD outpatients.[@b15-copd-13-2279] This audit highlighted the variability in medical prescriptions for COPD in pulmonologists' outpatient clinics,[@b16-copd-13-2279] showing the patterns of prescriptions and the determinants that led to treatment changes. However, the sample size was limited and the authors suggested that a nationwide analysis would be needed to confirm the results.

EPOCONSUL is a nationwide clinical audit aiming at evaluating clinical care delivered to COPD patients and describing the degree of adjustment to clinical guides in the outpatient secondary care setting.[@b17-copd-13-2279] By using the EPOCONSUL database, we aimed to describe pharmacological prescriptions (inhaled and oral) during a routine clinical visit for COPD, understand the distribution in different patient types, and study the determinants of changing therapy in daily clinical practice. The results of the analysis might help clinical and health care managers to understand medical prescription and improve clinical care in COPD patients.

Methods
=======

The methodology of EPOCONSUL has been thoroughly reported previously.[@b17-copd-13-2279] Briefly, EPOCONSUL is a clinical audit that evaluates health care for outpatients with COPD in the field of specialized outpatient clinics of pneumology. It is, therefore, an observational study with prospective case recruitment and cross-sectional analysis. The sample was selected from May 2014 to May 2015 from patients seen in an outpatient clinic of the participating centers. The recruitment of patients was prospective. With the idea of having information on the whole year, the inclusion was made in bimonthly periods. At the beginning of each of these bimonthly periods, each researcher included the first 10 patients in the clinic who had an established diagnosis of COPD and who were being followed up by this outpatient clinic. Inclusion criteria required patients to have a confirmed diagnosis of COPD, including being smokers or ex-smokers with an exposure of at least 10 pack-years, \>40 years old, and presenting with chronic respiratory symptoms suggestive of COPD together with a nonreversible bronchial obstruction by performing a postbronchodilator spirometry with a forced expiratory volume in 1 second (FEV~1~)/forced vital capacity (FVC) ratio \<0.7. In those cases, where no broncho-reversibility tests were available, it was also accepted as diagnostic criteria to have an FEV~1~/FVC ratio of \<0.7, together with an FEV~1~ value of \<80%. The project considered to exclude patients who had a follow-up time of \<1 year and patients who were already actively participating in another COPD-related research project. All the information during the audit was historical for the data on the clinical performance. However, the information regarding hospital resources was concurrent.

The protocol was approved by the ethics committee of the San Carlos Clinical Hospital (Madrid, Spain, internal code 14/030-E). This approval certified that the present study complied with the ethical principles formulated in the Declaration of Helsinki. In addition, it considered the preservation of the confidentiality of patient data as an important pillar. The protocol was also approved by the local ethics committee of each participating hospital. Currently, research laws in Spain (the Biomedical Research Act of 2007 and the Data Protection Act of 1999) explicitly state that individual consent is not necessary for retrospective evaluations of data obtained from routine clinical care for audit and research purposes, as in our study. For this reason, the signing of written informed consent by the included patients was not required. Likewise, the audited physicians were not informed about the clinical audit in order to preserve the usual clinical practice and the blinding of the clinical performance evaluation. The patient's data were coded, and their confidentiality was conserved in accordance with Spanish laws. The Scientific Committee had the responsibility to guarantee the scientific and methodological precision of the study and the quality control of all the collected data.

For the present study, prescription patterns were analyzed. Inhaled treatment plans were divided into six categories: those patients with no prescriptions of any inhaled medication, treatment with one LABD, treatment with ICS alone, two LABD, LABD--ICS therapies, and triple therapy (long-acting muscarinic antagonists \[LAMA\] + long-acting beta 2 agonists \[LABA\] + ICS). Since the efficacy of inhaled drugs has been shown to be similar regardless of the administration in single or different inhalers,[@b18-copd-13-2279]--[@b21-copd-13-2279] we considered these groups when prescribed together in one single inhaler or not. Asthma--COPD overlap was defined as in the Spanish National COPD Guideline (GesEPOC).[@b22-copd-13-2279]

Incorrect therapeutic schemes were also explored. Since the current Global Initiative for Obstructive Lung Disease (GOLD) 2017 A--D patient type classification is not specific enough to evaluate the correctness of a prescription at the patient level,[@b23-copd-13-2279] we identified incorrect prescriptions as those B--D patients not receiving LABD, patients receiving ICS alone, or those with same-class medications in different inhalers.

During the audited clinical visit, treatments that patients were receiving before the visit and changes taken after the visit were noted. Treatment changes were noted according to the following groups: cases with no change in the therapeutic scheme, step-up therapies, changes for a similar therapeutic scheme, and step-down changes. Step-up and -down changes were focused on three aspects: modifying the number or dose of LABD, modifying the number or dose of ICS, modifying the prescription of roflumilast, and other nonspecified changes not specifically recorded.

Statistics
----------

Statistical computations were performed using IBM SPSS Statistics (IBM Corporation, Armonk, NY, USA). Descriptive analysis was summarized by using the absolute (relative) frequencies of the categories for categorical variables and mean (standard deviation) for numerical ones. The variability was expressed as interhospital range (IHR), expressing the maximal and minimal average value in every participating center. By showing the maximal and minimal average value, information on the variability of the different parameters evaluated by the center was provided. The significance of this variability was explored by the analysis of variance (ANOVA) test or the chi-squared test depending on the nature of the variable.

The description of the inhaled therapeutic groups was referred to the complete cohort; however, the prescription of the oral therapies was referred to the population in each inhaled therapy group. A description of the therapeutic changes was done by showing the percentages of cases stepping-up or stepping-down, with these percentages being referred to both the whole cohort and the number of subjects within each therapeutic option. Factors associated with stepping-up or stepping-down were explored as covariates in a bivariate analysis using unpaired *t*-test or chi-squared test depending on the nature of the variable. These significant associations were entered in a stepwise backward, binomial, multivariate, logistic regression model. Two models were built with step up and step down as the dependent variables. Results were expressed as odds ratio (OR) with 95% confidence intervals (CIs). Alpha error was set at 0.05.

Results
=======

The EPOCONSUL cohort was composed of 4,508 COPD patients. The characteristics of the patients in the cohort have been previously reported.[@b17-copd-13-2279] For the present analysis, 60 cases were excluded due to having inconsistent data regarding pharmacological therapies. Therefore, 4,448 cases formed our population sample ([Table 1](#t1-copd-13-2279){ref-type="table"}). The prescription of the different inhaled therapy groups in the cohort is shown in [Figure 1](#f1-copd-13-2279){ref-type="fig"} and distributed as follows: no treatment prescribed or recorded, 124 cases (2.8%; IHR: 0%--36.7%; *p* \< 0.001); one LABD, 511 cases (11.5%; IHR: 0%--33.3%; *p* \< 0.001); ICS alone, five cases (0.1%; IHR: 0%--3.2%; *p* = 0.210); two LABD, 991 cases (22.3%; IHR: 8.3%--72.6%; *p* \< 0.001); LABD--ICS, 389 cases (8.6%; IHR: 0%--26.9%; *p* \< 0.001); and triple therapy, 2,428 cases (53.9%; IHR: 0%--78.7%; *p* \< 0.001). Altogether, 1,502 cases (34.6%; IHR: 13.3%--100%; *p* \< 0.001) received LABD therapy (one or two LABD) without ICS and 2,822 cases (62.6%; IHR: 9.5%--85.0%; *p* \< 0.001) received any form of ICS. Interestingly, 36 (0.8% in the complete cohort; 9.3% in those receiving LABD--ICS therapy) cases were receiving a combination of an LAMA and an ICS, 107 (2.4% in the complete cohort; 4.4% in those receiving triple therapy) cases were receiving triple therapy with all the three drugs in different inhalers, and 332 (7.5% in the complete cohort; 33.5% in those receiving double bronchodilator therapy) cases were receiving two bronchodilators in different inhalers.

Incorrect prescriptions of inhaled therapies were observed in 261 cases (5.9%; IHR: 0%--55.0%; *p* \< 0.001): 25 cases (0.6%; IHR: 0%--14.3%; *p* \< 0.001) due to not receiving LABD in GOLD B--D patients, 5 cases (0.1; IHR: 0%--3.2%; *p* \< 0.001) due to receiving ICS alone, and 231 cases (5.2%; IHR: 0%--55.0%; *p* \< 0.001) for receiving duplicate therapies.

The prescription of oral treatments is shown in [Figure 2](#f2-copd-13-2279){ref-type="fig"} and was distributed as follows (percentages referred to the complete cohort): roflumilast 383 (8.6%; IHR: 0%--31.0%; *p* \< 0.001), methylxanthines 282 (6.3%; IHR: 0%--23.2%; *p* \< 0.001), mucolytics 277 (6.2%; IHR: 0%--31.0%; *p* \< 0.001), and antibiotics 174 (3.9%; IHR: 0%--20.0%; *p* \< 0.001). The distribution of oral therapies according to the inhaled therapy groups is summarized in [Figure 2](#f2-copd-13-2279){ref-type="fig"}. There was some overlap in the prescription of oral therapies, but this was \<1% in all patient types, inhaled medication groups, and oral combinations (data not shown).

GOLD patient types were available in 2,613 cases: 681 (15.3%) GOLD A, 782 (17.7%) GOLD B, 256 (5.7%) GOLD C, and 894 (20.0%) GOLD D. The distribution of inhaled and oral therapies according to GOLD 2017 A--D patient groups is summarized in [Figures 3](#f3-copd-13-2279){ref-type="fig"} and [4](#f4-copd-13-2279){ref-type="fig"}. Triple therapy was the leading treatment in all GOLD 2017 patient types, followed by double bronchodilator therapy. In GOLD A patients, single bronchodilation and double bronchodilation were close and not far from triple therapies. In the rest of the GOLD 2017 patient types, there was a progressive increase in triple therapy and a progressive decrease in double bronchodilation. Regarding oral therapies, mucolytics were more frequently used in patients with a lower intensity of inhaled therapies, whereas usage of roflumilast increased in more severe cases.

Treatment changes during the audited visit are summarized in [Table 2](#t2-copd-13-2279){ref-type="table"}. After the clinical visit audited, 3,494 cases (77.5%; IHR: 3.3%--98.4%; *p* \< 0.001) did not modify their therapeutic prescription, 307 cases (6.8%; IHR: 0%--66.7%; *p* \< 0.001) had a step up, 238 cases (5.3%; IHR: 0%--26.7%; *p* \< 0.001) had a change for a similar scheme, 182 cases (4.1%; IHR: 0%--25.0%; *p* \< 0.001) had a step down, and 227 cases (5.1%; IHR: 0%--25.0%; *p* \< 0.001) had other nonspecified change.

Bivariate associations of clinical variables with step up or step down of therapy are shown in Tables S1 and S2, respectively. The multivariate analysis for stepping up is presented in [Table 3](#t3-copd-13-2279){ref-type="table"}. Clinical presentation, a positive response in the bronchodilator test, and previous triple therapy were significantly associated with stepping up. The multivariate analysis for stepping down is presented in [Table 4](#t4-copd-13-2279){ref-type="table"}. Exacerbations, previous treatment with LABD--ICS, and referral from secondary care were associated with stepping down. Interestingly, lung function was not found to be significantly associated.

Discussion
==========

Ours is the first nationwide clinical audit performed in Spain in specialized pulmonary outpatient clinics evaluating patterns of pharmacological prescription in COPD. The results of our analysis show that triple therapy continues being the most frequently prescribed pattern of medication and that the majority of prescribers do not modify therapeutic regimes in COPD patients after a routine clinical visit.

Clinical audits are complex processes framed in the concept of continuous improvement of the quality of care. These processes seek to improve patient care and its results through cyclical clinical practice evaluation strategies and results compared with recognized standards, subsequently completed through a process of implementing improvements.[@b24-copd-13-2279] According to current understanding, it is expected that health care professionals are able to receive comments on the performance of their usual practice. Although it might seem intuitive that a professional would be prone to modify their daily activities in the light of an evaluation of their quality of care, the real relevance of these changes may not have a great impact on clinical outcomes.[@b25-copd-13-2279] In this sense, one of the great remnants of clinical audits refers to the maintenance over time of this improvement achieved in clinical performance. From this idea, there is a need to establish continuous improvement strategies complemented with feedback that allow the establishment of clinical implementation programs.[@b26-copd-13-2279] Until now, the evaluation of clinical performance in COPD had focused on the hospitalized patient due to an exacerbation of the disease, probably because it is a potentially serious situation with important clinical repercussions for the patient and the health system. However, the situation in outpatient clinics has received much less attention.[@b15-copd-13-2279] Consequently, in the present study, the objective of the work was to advance in the assessment of quality assistance in the field of specialized external care and during a typical follow-up clinical visit.

The main strengths of our study are a nationwide coverage and a comprehensive, systematic evaluation of clinically relevant parameters together with resources and organizational aspects of clinical care. However, several methodological considerations must be observed in order to interpret our results correctly. In the first place, it is important to keep in mind that the clinical guidelines summarize the main norms for the diagnosis and treatment of a process. However, these are general recommendations that are not always based on evidence and do not always conform to all possible clinical presentations of the diseases. Therefore, it is usually common to find some kind of deviation from the recommendations in actual daily clinical practice. As a note, the degree of deviation from this general rule has not been quantified. Second, it is necessary to remember that a clinical audit evaluates the clinical information that a health personnel records in the clinical record. Therefore, an audit cannot identify measures carried out and that are not recorded in the clinical record. A clear example of this situation could be an evaluation of the inhalation technique that has been performed, but it has not been noted. In this regard, it is important to highlight the need to record all clinical actions with the goal that any health professional has all the relevant information available in the medical record. Third, this audit has had a cross-sectional analysis without evaluating the long-term clinical data. These data will undoubtedly serve as a basis for authors of the future audits to know the points on which to act and to study their long-term clinical impact. Likewise, the prospective impact of the adherence of the guide on the results should be another aspect of future evaluation in terms of rates of exacerbations and survival. In 2.8% of cases, there was no information on maintenance inhaled therapies. This finding has been previously reported, but with a considerable difference. A recent analysis of the medical records of 3,376 patients from general practice in Denmark revealed that 74.4% of them did not receive any maintenance inhaled medication even after spirometric confirmation of COPD.[@b27-copd-13-2279] In the UK, 28% of 20,154 patients, whose medical records were analyzed, in one study[@b6-copd-13-2279] and 20% of 29,815 patients in another study[@b7-copd-13-2279] received no initial pharmacological treatment. In Sweden, this figure was far below 10% in secondary care.[@b3-copd-13-2279] In the US, it has been reported that 55% of such patients did not receive inhaled maintenance therapy.[@b28-copd-13-2279] The reasons for this underprescription of maintenance inhaled therapies in COPD patients fall outside the scope of the present study and would require an ad hoc investigation, but could be partially explained by the type of center and the type of outpatient clinic available in these centers evaluating patients with specific characteristics.

Triple therapy keeps being the most prescribed medication even in A and B COPD patient types. Previous studies have highlighted the overuse of ICS and, in particular, triple therapy in COPD.[@b4-copd-13-2279],[@b5-copd-13-2279],[@b29-copd-13-2279] Although still high, the proportion of COPD patients with ICS has not been greatly reduced with previous studies reporting ICS use iñ60%[@b30-copd-13-2279] compared to 62.6% in our cohort. Indeed, it has been reported that only half of patients receiving ICS are doing this correctly prescribed.[@b31-copd-13-2279] Interestingly, the overprescription of triple therapy has been described in all clinical settings, primary and secondary care, different countries, and health systems. In our view, there are two reasons why this might be happening: 1) either we all do it wrongly in all countries and settings or 2) the guideline recommendations do not capture the complexity of the COPD patients, and there are other variables beyond lung function, symptoms, and exacerbations that influence clinicians in their medical decisions. Unfortunately, we do not have studies that can differentiate these two aspects of this controversy. Of note, one significant association with stepping down was the use of LABD--ICS, but not triple therapy, which might reflect a change in the clinical behavior of clinicians. In this regard, the variables associated with stepping up could reflect a trend toward a more personalized medicine in COPD in secondary care.

Duplicate therapies were the most frequently found error in inhaled medication prescription. In the present study, we were able to detect duplicated medications, ie, same-class repeats (eg, LABA--LAMA + ICS--LABA, LABA--LAMA + LABA, or LABA--ICS + ICS). Fortunately, the implementation of electronic prescription in Spain will probably help clinicians to correct all these prescriptions.[@b32-copd-13-2279]

After the clinical visit audited, 3,494 (77.5%) cases did not modify their therapeutic prescription. This result has been reported previously for our country. In a recent pilot clinical audit carried out in Spain, 64.8% cases saw no change in pharmacological treatment.[@b16-copd-13-2279] The high number of cases in which no drug prescribing modifications are carried out is another interesting debate. These are probably well-controlled patients with no exacerbations and few symptoms, and accordingly, we need to establish whether, when, and how in these cases a step down could be tried.[@b33-copd-13-2279] Although current recommendation documents suggest that stepping down can now be considered, currently there is no universally accepted consensus on how to perform this at the patient level.

Conclusion
==========

Ours is the first nationwide clinical audit performed in specialized pulmonary outpatient clinics evaluating pharmacological prescriptions in COPD. The results of our analysis show that the majority of chest physicians do not modify COPD therapeutic regimes after a routine clinical visit. Triple therapy in different inhalers continues being the most frequently prescribed medication pattern. The study highlights determinants of medical prescription in COPD, which require further research.
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###### 

Demographic and clinical characteristics of COPD participants

  Characteristics                 Average        IHR           *p*-value[a](#tfn1-copd-13-2279){ref-type="table-fn"}
  ------------------------------- -------------- ------------- -------------------------------------------------------
  Gender (male)                   3,823 (85.9)   60.0--100     \<0.001
  Age (years)                     69.7 (9.7)     63.0--75.4    \<0.001
  Active smokers (n)              1,029 (23.1)   6.5--38.1     \<0.001
  Tobacco exposure (pack-years)   56.1 (33.7)    28.3--106.3   \<0.001
  Body mass index (kg/m^2^)       28.0 (5.4)     25.2--38.5    \<0.001
  Comorbidities (Charlson)        2.9 (2.1)      1.7--4.7      \<0.001
  FVC (%)                         77.4 (20.9)    49.0--117     \<0.001
  FEV~1~ (%)                      54.0 (18.5)    36.0--86.0    \<0.001
  FEV~1~ reversibility (%)        9.7 (9.5)      3.1--15.4     \<0.001
  FEV~1~/FVC (%)                  52.3 (11.7)    65--47.9      \<0.001

**Notes:**

Calculated for variability with chi-squared test of ANOVA depending on the nature of the variable. Values are expressed as mean (standard deviation) or absolute (relative) frequencies according to the nature of the variable.

**Abbreviations:** ANOVA, analysis of variance; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; IHR, interhospital range.

###### 

Description of treatment changes during the audited visit

  Basal treatment                                                              No change            Step up        Similar                   Step down        Others: not specified                   
  ---------------------------------------------------------------------------- -------------------- -------------- ------------------------- ---------------- ----------------------- --------------- ----------------
  No inhaled treatment (n = 124)[c](#tfn5-copd-13-2279){ref-type="table-fn"}   88 (71.0; 2.0)       Increase ICS   2 (1.6; 0.04)             0                Decrease ICS            3 (2.4; 0.1)    6 (4.8; 0.1)
  Increase BD                                                                  19 (15.3; 0.4)                      Decrease BD               5 (4.0; 0.1)                                             
  Add roflumilast                                                              1 (0.8; 0.02)                       Discontinue roflumilast   0                                                        
  One LABD (n = 511)                                                           430 (84.1; 9.7)      Increase ICS   14 (2.7; 0.3)             11 (2.2; 0.2)    Decrease ICS            0               21 (4.1; 0.5)
  Increase BD                                                                  27 (5.3; 0.6)                       Decrease BD               8 (1.6; 0.2)                                             
  Add roflumilast                                                              0                                   Discontinue roflumilast   0                                                        
  ICS alone (n = 5)                                                            3 (60.0; 0.1)        Increase ICS   1 (20.0; 0.02)            0                Decrease ICS            0               1 (20.0; 0.02)
  Increase BD                                                                  0                                   Decrease BD               0                                                        
  Add roflumilast                                                              0                                   Discontinue roflumilast   0                                                        
  Two LABD (n = 991)                                                           744 (75.1; 16.7)     Increase ICS   30 (3.0; 0.7)             80 (8.1; 1.8)    Decrease ICS            0               52 (5.2; 1.2)
  Increase BD                                                                  60 (6.1; 1.3)                       Decrease BD               21 (2.1; 0.5)                                            
  Add roflumilast                                                              4 (0.4; 0.1)                        Discontinue roflumilast   0                                                        
  LABD--ICS (n = 389)                                                          284 (73.0; 6.3)      Increase ICS   8 (2.1; 0.2)              13 (3.3; 0.3)    Decrease ICS            15 (3.9; 0.3)   17 (4.4; 0.4)
  Increase BD                                                                  35 (9.0; 0.8)                       Decrease BD               14 (3.6; 0.3)                                            
  Add roflumilast                                                              2 (0.5; 0.04)                       Discontinue roflumilast   1 (0.3; 0.02)                                            
  Triple therapy (n = 2,428)                                                   1,945 (80.1; 43.1)   Increase ICS   29 (1.2; 0.6)             134 (5.5; 3.0)   Decrease ICS            72 (3.0; 1.6)   130 (5.4; 2.9)
  Increase BD                                                                  54 (2.2; 1.2)                       Decrease BD               31 (1.3; 0.7)                                            
  Add roflumilast                                                              21 (0.9; 0.5)                       Discontinue roflumilast   12 (0.5; 0.3)                                            
  Total (n = 4,448)                                                            3,494 (78.6)         Increase ICS   84 (1.9)                  238 (5.4)        Decrease ICS            90 (2.0)        227 (5.1)
  Increase BD                                                                  195 (4.4)                           Decrease BD               79 (1.8)                                                 
  Add roflumilast                                                              28 (0.6)                            Discontinue roflumilast   13 (0.3)                                                 

**Notes:**

Percentage within the basal treatment group.

Percentage within the whole cohort.

Patients not receiving inhaled medication or with no information in the medical record. An increase reflects an augment in the number or the dose of the drugs. A decrease denotes the decrement in the number or the dose of the drugs.

**Abbreviations:** BD, bronchodilators; ICS, inhaled corticosteroid; LABD, long-acting bronchodilator.

###### 

Multivariate analysis with factors associated with stepping up

  Factors                                                   Crude   Adjusted               
  --------------------------------------------------------- ------- -------------- ------- --------------
  Chronic bronchitis                                        1.298   1.029--1.638   1.315   0.995--1.635
  Asthma-like symptoms                                      1.479   1.157--1.891   1.315   1.010--1.712
  Positive BDT                                              2.397   1.598--3.596   2.119   1.393--3.224
  No inhaled treatment                                      3.057   1.899--4.921   1.938   1.182--3.175
  Triple therapy                                            0.401   0.314--0.511   0.370   0.285--0.479
  Phenotype: ACO                                            1.823   1.256--2.647   1.900   1.265--2.854
  Phenotype: frequent exacerbator with chronic bronchitis   1.557   1.120--2.164   2.148   1.498--3.082
  Time since previous visit (months)                        1.000   1.000--1.001   1.000   1.000--1.001

**Abbreviations:** ACO, asthma and COPD overlap; BDT, bronchodilator test; CI, confidence interval; OR, odds ratio.

###### 

Multivariate analysis with factors associated with stepping down

  Factors                                   Crude   Adjusted                
  ----------------------------------------- ------- -------------- -------- ---------------
  Latest available spirometry: FEV~1~ (%)   1.008   0.974--1.043   1.025    1.010--1.040
  Current spirometry: FVC \<80%             1.765   1.150--2.710   2.307    1.193--4.463
  ICS--LABD treatment                       2.148   1.431--3.224   12.467   5.262--29.538
  Triple inhaled therapy                    1.449   1.066--1.970   6.546    2.983--14.368
  Phenotype: nonexacerbator                 2.110   1.539--2.894   2.571    1.501--4.403
  COPD-dedicated outpatient clinic          1.585   1.151--2.183   1.701    0.967--2.994

**Abbreviations:** CI, confidence interval; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroid; LABD, long-acting bronchodilator; OR, odds ratio.
